MEN1 and pancreatic neuroendocrine tumor: Current treatments of pancreatic, foregut, and pituitary NETs are unsatisfactory, with a surgical cure for pancreatic NETs being rarely achieved, as the tumors have metastasized in greater than 50% of patients with MEN1 at presentation, and with pituitary NETs being more aggressive and resistant to treatment in patients with MEN1 (4, 12, –, 14).